Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies

Yusuke Yoshikawa(Kyoto University), Takeshi Kimura(Municipal Hirakata City Hospital), Hirotoshi Watanabe(Municipal Hirakata City Hospital), Hirokazu Kondo(Tenri Hospital), Takeshi Morimoto(Hyogo Medical University), Toshihiro Tamura(Tenri Hospital), Masahiro Natsuaki(Saga University), Yoshihisa Nakagawa(Tenri Hospital), Hiroki Shiomi(Kyoto University)
Circulation
October 6, 2017
10.1161/circulationaha.117.028924
Cited by 53

Related Papers

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|830
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
|The Lancet|2018|357
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease
|Circulation Journal|2020|345
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease
|Thrombosis and Haemostasis|2020|334
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
|JAMA Cardiology|2022|296